Marinus Pharmaceuticals (MRNS) News Today $0.23 -0.01 (-3.56%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $4.79December 17, 2024 | americanbankingnews.comMarinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic DevelopmentsNovember 21, 2024 | msn.comUS$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest ResultsNovember 16, 2024 | uk.finance.yahoo.comMarinus (MRNS) Initiated with a Buy at Cantor FitzgeraldNovember 14, 2024 | markets.businessinsider.comHold Rating on Marinus Pharmaceuticals Amid Strategic Uncertainty and TRUST-TSC Study SetbacksNovember 14, 2024 | markets.businessinsider.comAbout Marinus PharmaceuticalsNovember 13, 2024 | businesswire.comMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deMarinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC TrialOctober 30, 2024 | msn.comJefferies Downgrades Marinus Pharmaceuticals (MRNS)October 26, 2024 | msn.comTD Cowen Downgrades Marinus Pharmaceuticals (MRNS)October 26, 2024 | msn.comMarinus Pharmaceuticals price target lowered to $4 from $13 at Cantor FitzgeraldOctober 25, 2024 | markets.businessinsider.comMarinus Pharmaceuticals price target lowered to $1 from $3 at RBC CapitalOctober 25, 2024 | markets.businessinsider.comMarinus Pharmaceuticals (NASDAQ:MRNS) Given Neutral Rating at HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Marinus Pharmaceuticals in a report on Friday.October 25, 2024 | marketbeat.comMarinus Pharmaceuticals downgraded to Market Perform at JMP SecuritiesOctober 25, 2024 | markets.businessinsider.comMarinus Pharmaceuticals downgraded to Hold from Buy at JefferiesOctober 25, 2024 | markets.businessinsider.comMarinus Pharmaceuticals price target lowered to $3 from $23 at EF HuttonOctober 25, 2024 | markets.businessinsider.comJMP Securities Downgrades Marinus Pharmaceuticals (MRNS)October 25, 2024 | msn.comMarinus Pharmaceuticals Unveils Promising Phase 3 Trial Results for IV Ganaxolone in Treating Refractory Status EpilepticusOctober 22, 2024 | msn.comMarinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® PatentOctober 22, 2024 | msn.comMarinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration RegimensOctober 15, 2024 | businesswire.comMarinus Pharmaceuticals to Present New Epilepsy Treatment Data at Upcoming ConferenceOctober 15, 2024 | msn.comMarinus Pharmaceuticals Issues Stock Options to New EmployeeOctober 15, 2024 | msn.com3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity (MRNS)Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success.October 11, 2024 | marketbeat.comMarinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual MeetingOctober 9, 2024 | finance.yahoo.comMarinus Pharma (NASDAQ:MRNS) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.com621,625 Shares in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Bought by Renaissance Technologies LLCRenaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 621,625 shares of the biopharmaceutical company'sOctober 9, 2024 | marketbeat.comMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)October 8, 2024 | businesswire.comHere’s Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS)October 3, 2024 | finance.yahoo.comEF Hutton Acquisition Co. I Upgrades Marinus Pharmaceuticals (NASDAQ:MRNS) to Strong-BuyEF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a "strong-buy" rating in a report on Monday.October 2, 2024 | marketbeat.comWill Marinus Pharmaceuticals Be the Next Big Winner in Biotech?Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.October 1, 2024 | marketbeat.comEF Hutton Initiates Coverage of Marinus Pharmaceuticals (MRNS) with Buy RecommendationOctober 1, 2024 | msn.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of "Moderate Buy" by AnalystsMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight ratings firms that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and five have assigned a buy recommendationSeptember 30, 2024 | marketbeat.comSouthwest Airlines raises third-quarter revenue forecastSeptember 26, 2024 | ca.finance.yahoo.comGreat week for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) institutional investors after losing 78% over the previous yearSeptember 26, 2024 | finance.yahoo.comBuy Rating Affirmed for Marinus’s Ganaxolone: Promising TSC Treatment Poised for SuccessSeptember 26, 2024 | markets.businessinsider.comOppenheimer Upgrades Marinus Pharmaceuticals (MRNS)September 24, 2024 | msn.comMarinus Pharmaceuticals (NASDAQ:MRNS) Earns "Overweight" Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday.September 24, 2024 | marketbeat.comMarinus Pharmaceuticals: A Strong Buy on Promising TSC Treatment Prospects and High Success ProbabilitySeptember 23, 2024 | markets.businessinsider.comMarinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst DaySeptember 20, 2024 | businesswire.comMarinus Pharmaceuticals to Outline Strategic Vision at Investor & Analyst DaySeptember 19, 2024 | msn.comMarinus Pharmaceuticals to Present at 2024 Cantor Global Healthcare ConferenceSeptember 18, 2024 | msn.comMarinus Pharmaceuticals (NASDAQ:MRNS) Lifted to Hold at StockNews.comStockNews.com raised shares of Marinus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.September 18, 2024 | marketbeat.com695,972 Shares in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Purchased by Acadian Asset Management LLCAcadian Asset Management LLC purchased a new position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 695,972 shares of the biopharmaceutical company's stock, valued at approximatelSeptember 17, 2024 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Marinus (MRNS)September 16, 2024 | markets.businessinsider.comMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a research report on Monday.September 16, 2024 | marketbeat.comMarinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | finance.yahoo.comCantor Fitzgerald Reaffirms "Overweight" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a report on Monday.September 9, 2024 | marketbeat.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Rating of "Hold" by BrokeragesMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) has earned a consensus rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and three have given a buy rating to tSeptember 5, 2024 | marketbeat.comMarinus Pharmaceuticals Hosts Investor and Analyst DayAugust 27, 2024 | msn.comMarinus Pharmaceuticals (NASDAQ:MRNS) Downgraded by StockNews.com to "Sell"StockNews.com cut Marinus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday.August 22, 2024 | marketbeat.com Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin MRNS Media Mentions By Week MRNS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRNS News Sentiment▼0.000.60▲Average Medical News Sentiment MRNS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRNS Articles This Week▼15▲MRNS Articles Average Week Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Iterum Therapeutics News Today IO Biotech News Today Celularity News Today CASI Pharmaceuticals News Today Kezar Life Sciences News Today vTv Therapeutics News Today Omega Therapeutics News Today Exicure News Today Prelude Therapeutics News Today Atlantic Coastal Acquisition Corp. II News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRNS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRNS Stock Alerts